Marker Therapeutics (MRKR) EBIT (2010 - 2026)
Marker Therapeutics (MRKR) reported EBIT of -$4.1 million for Q1 2026, up 17.86% year-over-year from -$3.5 million in Q1 2025, and down 148.2% quarter-over-quarter from $8.4 million in Q4 2025.
Marker Therapeutics (MRKR) EBIT (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 16 years of EBIT data on file, last reported at -$4.1 million in Q1 2026.
- EBIT for Q1 2026 came in at -$4.1 million, up 17.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 million (up 56.55% YoY), and the FY2025 annual result was -$2.6 million, down 14.02% from the prior year.
- EBIT eased to -$4.1 million in Q1 2026 per MRKR's latest filing, from $8.4 million in the prior quarter.
- Over five years, EBIT peaked at $12.6 million in Q4 2022 and troughed at -$9.8 million in Q1 2022.
- A 5-year average of -$1.9 million and a median of -$3.2 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2024: EBIT tumbled 123.32% in 2023, then soared 270.67% in 2024.
- A 5-year view of EBIT shows it stood at $12.6 million in 2022, then slumped by 123.32% to -$2.9 million in 2023, then soared by 270.67% to $5.0 million in 2024, then soared by 68.51% to $8.4 million in 2025, then tumbled by 148.2% to -$4.1 million in 2026.
- Business Quant data shows MRKR's EBIT at -$4.1 million in Q1 2026, $8.4 million in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | -4.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.07 Mn |
| Dec 31, 2025 | 8.45 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | -4.26 Mn |
| Mar 31, 2025 | -4.96 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | -2.40 Mn |
| Jun 30, 2024 | -2.31 Mn |
| Mar 31, 2024 | -2.55 Mn |
| Dec 31, 2023 | -2.94 Mn |
| Sep 30, 2023 | -3.20 Mn |
| Jun 30, 2023 | -4.13 Mn |
| Mar 31, 2023 | -4.31 Mn |
| Dec 31, 2022 | 12.60 Mn |
| Sep 30, 2022 | -5.83 Mn |
| Jun 30, 2022 | -5.27 Mn |
| Mar 31, 2022 | -9.79 Mn |
| Dec 31, 2021 | -9.76 Mn |
| Sep 30, 2021 | -10.02 Mn |
| Jun 30, 2021 | -10.91 Mn |